Pleomorphic lobular carcinoma of the breast: Molecular pathology and clinical impact

Future Oncology

Volumn 5, Issue 2, 2009, Pages 233-243

  Vargas, Ana Cristina ^a   Lakhani, Sunil R ^a,b,c   Simpson, Peter T ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Breast cancer; E cadherin; Invasive lobular carcinoma; Morphological variant; Pleomorphic lobular carcinoma

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53; TRASTUZUMAB; UVOMORULIN;

BREAST BIOPSY; BREAST CARCINOMA; BREAST SURGERY; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MORTALITY; CANCER RECURRENCE; CARCINOMA CELL; CARCINOMA IN SITU; CHROMOSOME 11Q; CHROMOSOME 12Q; CHROMOSOME 16P; CHROMOSOME 16Q; CHROMOSOME 17Q; CHROMOSOME 1Q; CHROMOSOME 8Q; CHROMOSOME ABERRATION; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; INTRADUCTAL CARCINOMA; MOLECULAR BIOLOGY; OVERALL SURVIVAL; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; SURVIVAL TIME; BREAST TUMOR; FEMALE; GENE EXPRESSION; GENETICS; LUNG CARCINOMA; PATHOLOGY;

BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; GENE EXPRESSION; HUMANS;

EID: 66349109999     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.5.2.233     Document Type: Review

References (98)

1. Tavassoli FA, Devilee P: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, France (2003).
2. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW: Infiltrating lobular carcinoma of the breast. Histopathalogy 6(2), 149-161 (1982).
3. Page DL, Anderson TJ, Sakamoto G: Infiltrating carcinoma: major histological types. In: Diagnostic Histopathology of the Breast. Page DL, Anderson TJ (Eds). Churchill Livingston, NY, USA, 193-235 (1987).
4. Eusebi V, Magalhaes F, Azzopardi JG: Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum. Pathol. 23(6), 655-662 (1992).
5. Weidner N, Semple JP: Pleomorphic variant of invasive lobular carcinoma of the breast. Hum. Pathol. 23(10), 1167-1171 (1992).
6. Bentz JS, Yassa N, Clayton F: Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod. Pathol. 11(9), 814-822 (1998).
7. Middleton LP, Palacios DM, Bryant BR, Krebs P, Otis CN, Merino MJ: Pleomorphic-lobular carcinoma: morphology, immunohistochemistry, and molecular analysis. Am. J. Surg. Pathol. 24(12), 1650-1656 (2000).
8. Ellis IQ, Schnitt SJ, Sastre-Garau X et al.: Invasive breast carcinomas. In: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Tavassoli FA, Devilee P (Eds). IARC Press, Lyon, France, 13-59 (2003).
9. Bratthauer GL, Moinfar F, Stamatakos MD et al.: Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Hum. Pathol. 33(6), 620-627 (2002).
10. Jacobs TW, Pliss N, Kouria G, Schnitt SJ: Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization. Am. J. Surg. Pathol. 25(2), 229-236 (2001).
11. Lehr HA, Folpe A, Yaziji H, Kommoss F, Gown AM: Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am. J. Clin. Pathol. 114(2), 190-196 (2000).
12. Maluf HM, Swanson PE, Koerner FC: Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis. Am. J. Surg. Pathol. 25(2), 237-244 (2001).
13. Da Silva L, Parry S, Reid L et al.: Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am. J. Surg. Pathol. 32(5), 773-783 (2008).
14. Wahed A, Connelly J, Reese T: E-cadherin expression in pleomorphic lobular carcinoma: an aid to differentiation from ductal carcinoma. Ann. Diagn. Pathol. 6(6), 349-351 (2002).
15. Goldstein NS, Bassi D, Watts JC, Layfield LJ, Yaziji H, Gown AM: E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am. J. Clin. Pathol. 115(4), 534-542 (2001).
16. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5), 403-410 (1991).
17. Sneige N, Wang J, Baker BA. Krishnamurthy S. Middleton LP: Clinical, histopathologic, and biologic features of pleomorphic lobular (ductal-lobular) carcinoma in situ of the breast: a report of 24 cases. Mod. Pathol. 15(10), 1044-1050 (2002).
18. Chivukula M, Haynik DM, Brufsky A, Carter G, Dabbs DJ: Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile. Am. J. Surg. Pathol. (2008).
19. Frost AR, Karcher DS, Terahata S, Siegel RS, Silverberg SG: DNA analysis and S-phase fraction determination by flow cytometric analysis of infiltrating lobular carcinoma of the breast. Mod. Pathol. 9(9), 930-937 (1996).
20. Rosen P: Lobular carcinoma in situ and atypical lobular hyperplasia. In: Rosen's Breast Pathology, 2nd Edition. Lippincott Williams and Wilkins, PA, USA, 581-626 (2001).
21. Sapino A, Frigerio A, Peterse JL, Arisio R, Coluccia C, Bussolati G: Mammographically detected in situ lobular carcinomas of the breast. Virchows Arch. 436(5), 421-430 (2000).
22. Fadare O: Pleomorphic lobular carcinoma in situ of the breast composed almost entirely of signet ring cells. Pathol. Int. 56(11), 683-687 (2006).
23. Chivukula M, Striebel JM, Ersahin C, Dabbs DJ: Evaluation of morphologic features to identify 'basil-like phenotype' on-core needle biopsies of breast. Appl. Immunohistochem. Mol. Morphol. 16(5), 411-416 (2008).
24. Dabbs DJ, Grenko RI, Silverman JF: Fine needle aspiration cytology of pleomorphic lobular carcinoma of the breast. Duct carcinoma as a diagnostic pitfall. Acta Cytol. 38(6), 923-926 (1994).
25. Auger M, Huttner I: Fine-needle aspiration cytology of pleomorphic lobular carcinoma of the breast. Comparison with the classic type. Cancer 81(1), 29-32 (1997).
26. Monaco SE, Dabbs DJ, Kanbour-Shakir A: Pleomorphic lobular carcinoma in pleural fluid: diagnostic pitfall for atypical mesothelial cells. Diagn. Cytopathol. 36(9), 657-661 (2008).
27. Joshi A, Kumar N, Verma K: Diagnostic challenge of lobular carcinoma on aspiration cytology. Diagn. Cytopathol. 18(3), 179-183 (1998).
28. Creager AJ, Geisinger KR, Perrier ND et al.: Intraoperative imprint cytologic evaluation of sentinel lymph nodes for lobular carcinoma of the breast. Ann. Surg. 239(1), 61-66 (2004).
29. Silver SA, Tavassoli FA: Pleomorphic carcinoma of the breast: clinicopathological analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma. Histopathology 36(6), 505-514 (2000).
30. Walford N, ten Velden J: Histiocytoid breast carcinoma: an apocrine variant of lobular carcinoma. Histopathology 14(5), 515-522 (1989).
31. Fujiwara M, Horiguchi M, Mori S et al.: Histiocytoid breast carcinoma: solid variant of invasive lobular carcinoma with decreased expression of both E-cadherin and CD44 epithelial variant. Pathol. Int. 55(6), 353-359 (2005).
32. Eusebi V, Betts C, Haagensen DE Jr, Gugliotta P, Bussolati G, Azzopardi JG: Apocrine differentiation in lobular carcinoma of the breast: a morphologic, immunologic, and ultrastructural study. Hum. Pathol. 15(2), 134-140 (1984).
33. Hayes MM, Seidman JD, Ashton MA: Glycogen-rich clear cell carcinoma of the breast. A clinicopathologic study of 21 cases. Am. J. Surg. Pathol. 19(8), 904-911 (1995).
34. Fisher ER, Tavares J, Bulatao IS, Sass R, Fisher B: Glycogen-rich, clear cell breast cancer: with comments concerning other clear cell variants. Hum. Pathol. 16(11), 1085-1090 (1985).
35. Raju U, Ma CK, Shaw A: Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study. Mod. Pathol. 6(5), 516-520 (1993).
36. Merino MJ, Livolsi VA: Signet ring carcinoma of the female breast: a clinicopathologic analysis of 24 cases. Cancer 48(8), 1830-1837 (1981).
37. Roylance R, Gorman P, Harris W et al.: Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res. 59(7), 1433-1436 (1999).
38. Loo LW, Grove DI, Williams EM et al.: Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res. 64(23), 8541-8549 (2004).
39. Stange DE, Radlwimmer B, Schubert F et al.: High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin. Cancer Res. 12(2), 345-352 (2006).
40. Buerger H, Otterbach F, Simon R et al.: Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J. Pathol. 189(4), 521-526 (1999).
41. Simpson PT, Reis-Filho JS, Lambros MB et al.: Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular generic pathway with classic lobular carcinomas. J. Pathol. 215(3), 231-244 (2008).
42. Reis-Filho JS, Simpson PT, Jones C et al.: Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J. Pathol. 207(1), 1-13 (2005).
43. Nishizaki T, Chew K, Chu L et at.: Genetic alterations in lobular breast cancer by comparative genomic hybridization. Int. J. Cancer 74(5), 513-517 (1997).
44. Shelley Hwang E, Nyante SJ, Yi Chen Y et al.: Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer 100(12), 2562-2572 (2004).
45. Reis-Filho JS, Simpson PT, Turner NC et al.: FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 12(22), 6652-6662 (2006).
46. Bergamaschi A, Kim YH, Wang P et al.: Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45(11), 1033-1040 (2006).
47. Fridlyand J, Snijders AM, Ylstra B et al.: Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 6, 96 (2006).
48. Chin K, DeVries S, Fridlyand J et al.: Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10(6), 529-541 (2006).
49. Borst MJ, Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 114(4), 637-641; discussion 641-632 (1993).
50. Lamovec J, Bracko M: Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J. Surg. Oncol., 48(1), 28-33 (1991).
51. Aberle H, Schwartz H, Kemler R: Cadherin-catenin complex: protein interactions and their implications for cadherin function. J. Cell. Biochem. 61(4), 514-523 (1996).
52. Chen X, Kojima S, Borisy GG, Green KJ: p120 catenin associates with kinesin and facilitates the transport of cadherin-catenin complexes to intercellular junctions. J. Cell. Biol. 163(3), 547-557 (2003).
53. Davis MA, Ireton RC, Reynolds AB: A core function for p120-catenin in cadherin turnover. J. Cell. Biol. 163(3), 525-534 (2003).
54. Ireton RC, Davis MA, van Hengel J et al.: A novel role for p120 catenin in E-cadherin function. J. Cell. Biol. 159(3), 465-476 (2002).
55. Noren NK, Liu BP, Burridge K, Kreft B: p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J. Cell. Biol. 150(3), 567-580 (2000).
56. Peifer M, Yap AS: Traffic control: p120-catenin acts as a gatekeeper to control the fate of classical cadherins in mammalian cells. J. Cell. Biol. 163(3), 437-440 (2003).
57. Reynolds AB, Daniel J, McCrea PD, Wheelock MJ, Wu J, Zhang Z: Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mol. Cell. Biol. 14(12), 8333-8342 (1994).
58. Sarrio D, Moreno-Bueno G, Hardisson D et al.: Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int. J. Cancer 106(2), 208-215 (2003).
59. Sarrio D, Perez-Mies B, Hardisson D et al.: Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 23(19), 3272-3283 (2004).
60. De Leeuw WJ, Berx G, Vos CB et al.: Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J. Pathol. 183(4), 404-411 (1997).
61. Dabbs DJ, Bhargava R, Chivukula M: Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin. Am. J. Surg. Pathol. 31(3), 427-437 (2007).
62. Dabbs DJ, Kaplai M, Chivukula M, Kanbour A, Kanbour-Shakir A, Carter GJ: The spectrum of morphomolecular abnormalities of the E-cadherin/catenin complex in pleomorphic lobular carcinoma of the breast. Appl. Immunohistochem. Mol. Morphol. 15(3) 260-266 (2007).
63. Berx G, Cleton-Jansen AM, Strumane K et al.: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13(9), 1919-1925 (1996).
64. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR: Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int. J. Cancer 92(3), 404-408 (2001).
65. Aigner K, Dampier B, Descovich L et al.: The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 26(49), 6979-6988 (2007).
66. Etzell JE, Devries S, Chew K et al.: Loss of chromosome 16q in lobular carcinoma in situ. Hum. Pathol. 32(3), 292-296 (2001).
67. Lakhani SR, Collins N, Sloane JP, Stratton MR: Loss of heterozygosity in lobular carcinoma in situ of the breast. Clin. Mol. Pathol. 48(2), M74-M78 (1995).
68. Vos CB, Cleton-Jansen AM, Berx G et al.: E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br. J. Cancer 76(9), 1131-1133 (1997).
69. Palacios J, Sarrio D, Garcia-Macias MC, Bryant B, Sobel ME, Merino MJ: Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod. Pathol. 16(7), 674-678 (2003).
70. Herschkowitz JI, Simin K, Weigman VJ et al.: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8(5), R76 (2007).
71. Sarrio D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 68(4), 989-997 (2008).
72. Mahler-Araujo B, Savage K, Parry S, Reis-Filho JS: Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotype. J. Clin. Pathol. 61(5), 615-620 (2008).
73. Nielsen TO, Hsu FD, Jensen K et al.: Imunohistochemical and clinical characterization - of the has, al-like subtype, invasive breast carcinoma. Clin. Cancer Res. 10(16), 5367-5374 (2004).
74. Palacios J, Benito N, Pizarro A et al.: Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am. J. Pathol. 146(3), 605-612 (1995).
75. Frolik D, Caduff R, Varga Z: Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes an tumour suppressor genes compared with invasive ductal, carcinomas and classical infiltrating lobular carcinomas. Histopathology 39(5), 503-513 (2001).
76. Varga Z, Zhao J, OhIschlegel C, Odermatt B, Heitz PU: Preferential HER-2/ neu o overexpression, and/or-amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 44(4), 332-338 (2004).
77. Buchanan CL, Flynn LW, Murray MP et a: Is pleomorphic lobular carcinoma really a distinct clinical entity? J. Surg. Oncol., 98(5), 314-317 (2008).
78. Radhi JM: Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR. Histopathology 36(2), 156-160 (2000).
79. Weigelt B, Horlings H, Kreike B et al.: Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 216(2), 141-150 (2008).
80. Rakha EA, El-Sayed ME, Powe DG et al.: Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes. Eur. J. Cancer 44(1), 73-83 (2008).
81. Fadate O, Wang SA, Hileeto D: The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-file subset? Hum., Pathol. 39(3), 331-336 (2008).
82. Ferlicot S, Vincent-Salomon A, Medioni J et al.: Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur. J. Cancer 40(3), 336-341 (2004).
83. Armes JE, Egan AJ, Southey MC et al.: The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and withiat BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83(11), 2335-2345 (1998).
84. Gelsi-Boyer V, Orsetti B, Cervera N et al.: Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol. Cancer Res. 3(12), 655-667 (2005).
85. Ormandy CJ, Musgrove EA, Hui R, Daly RJ, Sutherland RL: Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res. Treat. 78(3), 323-335 (2003).
86. McCann AH, Kirley A, Carney DN et al.: Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer 71(5), 981-985 (1995).
87. Nordgard SH, Johansen FE, Alnaes GI et al.: Genome-wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients. Genes Chromosomes Cancer 47(8), 680-696 (2008).
88. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J. Pathol. 205(2), 248-254 (2005).
89. Orvieto E, Maiorano E, Bottiglieri L et al.: Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 113(7), 1511-1520 (2008).
90. du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, Blamey RW: Invasive lobular carcinomas of the breast - the prognosis of histopathological subtypes. Br. J. Cancer 60(4), 605-609 (1989).
91. DiCostanzo D, Rosen PP, Gareen I, Franklin S, Lesser M: Prognosis in infiltrating lobular carcinoma. An analysis of 'classical' and variant tumors. Am. J. Surg. Pathol. 14(1), 12-23 (1990).
92. Rakha EA, El-Sayed ME, Menon S, Green AR, Lee AH, Ellis IO: Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res. Treat. 111(1), 121-127 (2008).
93. Bane AL, Tjan S, Parkes RK, Andrulis I, O'Malley FP: Invasive lobular carcinoma: to grade or not to grade. Mod. Pathol. 18(5), 621-628 (2005).
94. Moe RE, Anderson BO: Distinctive biology of pleomorphic lobular carcinoma of the breast. J. Surg. Oncol. 90(2), 47-50 (2005).
95. Mahtani RL, Vogel CL: Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab - coincidence or hint? J. Clin. Oncol. 26(35), 5823-5824 (2008).
96. Jacobs TW, Connolly JL, Schnitt SJ: Nonmalignant lesions in breast core needle biopsies: to excise or not to excise? Am. J. Surg. Pathol. 26(9), 1095-1110 (2002).
97. Menon S, Porter GJ, Evans AJ et al.: The significance of lobular neoplasia on needle core biopsy of the breast. Virchows Arch. 452(5), 473-479 (2008).
98. Middleton LP, Grant S, Stephens T, Stelling CB, Sneige N, Sahin AA: Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised? Mod. Pathol. 16(2), 120-129 (2003).